Strattera Starting Dose for Adults
Start atomoxetine at 40 mg/day for the first 7 days, then increase to a target dose of 80 mg/day. 1
Initial Dosing Strategy
The FDA-approved dosing regimen for adults begins with:
- 40 mg/day for 7 days (initial dose)
- Increase to 80 mg/day after the first week (target dose)
- Maximum dose: 100 mg/day if needed after 2-4 additional weeks at 80 mg/day 1
This can be administered either as a single daily dose or divided into two doses (morning and late afternoon/early evening).
Critical Dosing Considerations
Reaching the target dose of 80 mg/day is essential for treatment success. Real-world data show that only 45% of adults on monotherapy reach this recommended dose, yet those who do achieve 93.8 more days of therapy compared to those who don't 2. Adults who reach 80 mg/day have significantly longer treatment duration (159.3 vs 65.6 days) 2.
Time to Efficacy
- Small effect sizes appear by 1 week (0.28 effect size)
- Moderate effect sizes by 4 weeks (0.45 effect size) at target dose
- Continued improvement through 6 months (0.52 effect size overall; 0.82 in the 80 mg group) 3
Keep patients at the target dose of 80 mg/day for 4-6 weeks before judging efficacy 4. The medication demonstrates increasing effectiveness over time, with response rates continuing to rise throughout 26 weeks of treatment 3.
Dose Adjustments for Special Populations
Hepatic Impairment
- Moderate hepatic insufficiency (Child-Pugh B): Reduce to 50% of normal dose
- Severe hepatic insufficiency (Child-Pugh C): Reduce to 25% of normal dose 1
Renal Impairment
- No dose adjustment needed, even in end-stage renal disease 1
CYP2D6 Poor Metabolizers
- Consider slower titration or lower doses, as these patients have significantly higher drug exposure 1
Common Pitfalls to Avoid
Underdosing is the most common error. The average real-world adult dose is approximately 60 mg/day, well below the recommended 80 mg/day target 4. This suboptimal dosing leads to:
- Premature discontinuation due to perceived lack of efficacy
- Shorter treatment duration
- Reduced symptom improvement
Set appropriate patient expectations: Explain that full therapeutic effect develops gradually over 4-6 weeks, not immediately. This prevents premature discontinuation when patients don't see rapid results 4.
Tolerability Profile
The most common adverse effects at therapeutic doses include dry mouth, insomnia, nausea, decreased appetite, constipation, and dizziness 5. In Japanese adults, atomoxetine up to 120 mg/day showed only a 6.7% discontinuation rate due to adverse events 6. These side effects are generally manageable and should not prevent reaching the target dose.